Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus

32Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Patent ductus arteriosus is one of the most common congenital abnormalities found in premature infants. Ibuprofen, a nonsteroidal drug that is commonly used as an antipyretic, analgesic and anti-inflammatory agent, is also used to induce closure of symptomatic patent ductus arteriosus in preterm infants. Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension. Only 3 cases of pulmonary hypertension following early administration of an ibuprofen solution buffered with tromethamine have previously been reported. However, this severe side effect has never been observed in multicentre, randomized, double-blind controlled trials, nor in recent reviews or meta-analyses of L-lysine ibuprofen use. © 2006 CMA Media Inc.

Cite

CITATION STYLE

APA

Bellini, C., Campone, F., & Serra, G. (2006). Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. CMAJ. Canadian Medical Association Journal, 174(13), 1843–1844. https://doi.org/10.1503/cmaj.051446

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free